A detailed history of Vanguard Group Inc transactions in Veracyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 7,496,981 shares of VCYT stock, worth $253 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,496,981
Previous 7,384,871 1.52%
Holding current value
$253 Million
Previous $164 Million 0.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$18.86 - $23.55 $2.11 Million - $2.64 Million
112,110 Added 1.52%
7,496,981 $162 Million
Q1 2024

May 10, 2024

BUY
$21.0 - $29.1 $5.6 Million - $7.76 Million
266,660 Added 3.75%
7,384,871 $164 Million
Q4 2023

Feb 14, 2024

BUY
$19.72 - $28.68 $1.04 Million - $1.51 Million
52,699 Added 0.75%
7,118,211 $196 Million
Q3 2023

Nov 14, 2023

BUY
$22.33 - $29.92 $477,527 - $639,839
21,385 Added 0.3%
7,065,512 $158 Million
Q2 2023

Aug 14, 2023

BUY
$20.96 - $26.99 $735,800 - $947,483
35,105 Added 0.5%
7,044,127 $179 Million
Q1 2023

May 15, 2023

BUY
$20.58 - $27.89 $3.22 Million - $4.36 Million
156,365 Added 2.28%
7,009,022 $156 Million
Q4 2022

Feb 10, 2023

BUY
$15.31 - $29.94 $1.48 Million - $2.89 Million
96,666 Added 1.43%
6,852,657 $163 Million
Q3 2022

Nov 14, 2022

BUY
$16.58 - $27.9 $863,768 - $1.45 Million
52,097 Added 0.78%
6,755,991 $112 Million
Q2 2022

Aug 12, 2022

BUY
$15.45 - $29.52 $1.47 Million - $2.8 Million
94,988 Added 1.44%
6,703,894 $133 Million
Q1 2022

May 13, 2022

BUY
$21.94 - $42.51 $297,550 - $576,520
13,562 Added 0.21%
6,608,906 $182 Million
Q4 2021

Feb 14, 2022

BUY
$36.09 - $53.79 $1.52 Million - $2.26 Million
42,019 Added 0.64%
6,595,344 $272 Million
Q3 2021

Nov 12, 2021

BUY
$35.62 - $52.97 $10.1 Million - $15 Million
283,076 Added 4.51%
6,553,325 $304 Million
Q2 2021

Aug 13, 2021

BUY
$32.94 - $56.62 $207 Million - $355 Million
6,270,249 New
6,270,249 $251 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.42B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.